Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Mar 6

PMID 33673034

Citations 47

Authors

Ines C Bras

Tiago F Outeiro

Affiliations

Soon will be listed here.

Abstract

The accumulation of misfolded alpha-synuclein (aSyn) throughout the brain, as Lewy pathology, is a phenomenon central to Parkinson's disease (PD) pathogenesis. The stereotypical distribution and evolution of the pathology during disease is often attributed to the cell-to-cell transmission of aSyn between interconnected brain regions. The spreading of conformationally distinct aSyn protein assemblies, commonly referred as strains, is thought to result in a variety of clinically and pathologically heterogenous diseases known as synucleinopathies. Although tremendous progress has been made in the field, the mechanisms involved in the transfer of these assemblies between interconnected neural networks and their role in driving PD progression are still unclear. Here, we present an update of the relevant discoveries supporting or challenging the prion-like spreading hypothesis. We also discuss the importance of aSyn strains in pathology progression and the various putative molecular mechanisms involved in cell-to-cell protein release. Understanding the pathways underlying aSyn propagation will contribute to determining the etiology of PD and related synucleinopathies but also assist in the development of new therapeutic strategies.

Citing Articles

A same day α-synuclein RT-QuIC seed amplification assay for synucleinopathy biospecimens.

Parveen S, Alam P, Orru C, Vascellari S, Hughson A, Zou W NPJ Biosens. 2025; 2(1):8.

PMID: 39950033 PMC: 11813799. DOI: 10.1038/s44328-024-00023-w.

Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies.

Kiersnowski O, Mattioli P, Argenti L, Avanzino L, Calizzano F, Diociasi A Sci Rep. 2025; 15(1):4186.

PMID: 39905067 PMC: 11794440. DOI: 10.1038/s41598-024-83593-z.

Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions.

Kuo G, Kumbhar R, Blair W, Dawson V, Dawson T, Mao X Mol Neurodegener. 2025; 20(1):10.

PMID: 39849529 PMC: 11756073. DOI: 10.1186/s13024-025-00797-1.

The α-Synuclein Seeding Amplification Assay for Parkinson's Disease.

Yi L, Tan E, Zhou Z Int J Mol Sci. 2025; 26(1.

PMID: 39796243 PMC: 11720040. DOI: 10.3390/ijms26010389.

Accumulation of alpha-synuclein pathology in the liver exhibits post-translational modifications associated with Parkinson's disease.

Hallbeck M, Ekmark-Lewen S, Kahle P, Ingelsson M, Reyes J iScience. 2024; 27(12):111448.

PMID: 39720536 PMC: 11667178. DOI: 10.1016/j.isci.2024.111448.

References

Jao C, Hegde B, Chen J, Haworth I, Langen R . Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci U S A. 2008; 105(50):19666-71. PMC: 2605001. DOI: 10.1073/pnas.0807826105. View

Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Shannon K, Keshavarzian A, Mutlu E, Dodiya H, Daian D, Jaglin J . Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2011; 27(6):709-15. DOI: 10.1002/mds.23838. View

Bernis M, Babila J, Breid S, Wusten K, Wullner U, Tamguney G . Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun. 2015; 3:75. PMC: 4660655. DOI: 10.1186/s40478-015-0254-7. View

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

Chu Y, Muller S, Tavares A, Barret O, Alagille D, Seibyl J . Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019; 142(11):3565-3579. PMC: 7962904. DOI: 10.1093/brain/awz296. View

Chen S, Drakulic S, Deas E, Ouberai M, Aprile F, Arranz R . Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci U S A. 2015; 112(16):E1994-2003. PMC: 4413268. DOI: 10.1073/pnas.1421204112. View

Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro T, Pepivani I . Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213(2):315-25. DOI: 10.1016/j.expneurol.2008.06.004. View

10.

Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U . Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2003; 249 Suppl 3:III/1-5. DOI: 10.1007/s00415-002-1301-4. View

11.

Lee J, Takahama S, Zhang G, Tomarev S, Ye Y . Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nat Cell Biol. 2016; 18(7):765-76. PMC: 10701763. DOI: 10.1038/ncb3372. View

12.

Winner B, Jappelli R, Maji S, Desplats P, Boyer L, Aigner S . In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011; 108(10):4194-9. PMC: 3053976. DOI: 10.1073/pnas.1100976108. View

13.

Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C . Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol. 2016; 74(2):163-172. DOI: 10.1001/jamaneurol.2016.4547. View

14.

Braak H, Muller C, Rub U, Ackermann H, Bratzke H, de Vos R . Pathology associated with sporadic Parkinson's disease--where does it end?. J Neural Transm Suppl. 2006; (70):89-97. DOI: 10.1007/978-3-211-45295-0_15. View

15.

Jucker M, Walker L . Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci. 2018; 21(10):1341-1349. PMC: 6375686. DOI: 10.1038/s41593-018-0238-6. View

16.

Vargas J, Grudina C, Zurzolo C . The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease. Ageing Res Rev. 2019; 50:89-101. DOI: 10.1016/j.arr.2019.01.012. View

17.

Polinski N, Volpicelli-Daley L, Sortwell C, Luk K, Cremades N, Gottler L . Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. J Parkinsons Dis. 2018; 8(2):303-322. PMC: 6004926. DOI: 10.3233/JPD-171248. View

18.

Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterova K . Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol. 2016; 263(11):2271-2277. DOI: 10.1007/s00415-016-8259-0. View

19.

Alvarez-Erviti L, Seow Y, Schapira A, Gardiner C, Sargent I, Wood M . Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011; 42(3):360-7. PMC: 3107939. DOI: 10.1016/j.nbd.2011.01.029. View

20.

Ulusoy A, Rusconi R, Perez-Revuelta B, Musgrove R, Helwig M, Winzen-Reichert B . Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med. 2013; 5(7):1119-27. PMC: 3721477. DOI: 10.1002/emmm.201302475. View